NASDAQ
VRDN

Viridian Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Viridian Therapeutics Inc Stock Price

Vitals

Today's Low:
$17.65
Today's High:
$18.58
Open Price:
$17.85
52W Low:
$17.49
52W High:
$39
Prev. Close:
$17.87
Volume:
750926

Company Statistics

Market Cap.:
$838.03 million
Book Value:
4.154
Revenue TTM:
$1.47 million
Operating Margin TTM:
-14326.46%
Gross Profit TTM:
$-99122000
Profit Margin:
0%
Return on Assets TTM:
-50.5%
Return on Equity TTM:
-86.47%

Company Profile

Viridian Therapeutics Inc had its IPO on 2014-06-18 under the ticker symbol VRDN.

The company operates in the Healthcare sector and Biotechnology industry. Viridian Therapeutics Inc has a staff strength of 86 employees.

Stock update

Shares of Viridian Therapeutics Inc opened at $17.85 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $17.65 - $18.58, and closed at $17.75.

This is a -0.67% slip from the previous day's closing price.

A total volume of 750,926 shares were traded at the close of the day’s session.

In the last one week, shares of Viridian Therapeutics Inc have slipped by -7.12%.

Viridian Therapeutics Inc's Key Ratios

Viridian Therapeutics Inc has a market cap of $838.03 million, indicating a price to book ratio of 4.2109 and a price to sales ratio of 588.21.

In the last 12-months Viridian Therapeutics Inc’s revenue was $1.47 million with a gross profit of $-99122000 and an EBITDA of $-210204000. The EBITDA ratio measures Viridian Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Viridian Therapeutics Inc’s operating margin was -14326.46% while its return on assets stood at -50.5% with a return of equity of -86.47%.

In Q2, Viridian Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 71.9%.

Viridian Therapeutics Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-5.04 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Viridian Therapeutics Inc’s profitability.

Viridian Therapeutics Inc stock is trading at a EV to sales ratio of 446.4291 and a EV to EBITDA ratio of -7.4628. Its price to sales ratio in the trailing 12-months stood at 588.21.

Viridian Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$351.47 million
Total Liabilities
$28.66 million
Operating Cash Flow
$40.71 million
Capital Expenditure
$331000
Dividend Payout Ratio
0%

Viridian Therapeutics Inc ended 2024 with $351.47 million in total assets and $0 in total liabilities. Its intangible assets were valued at $351.47 million while shareholder equity stood at $315.86 million.

Viridian Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $28.66 million in other current liabilities, 436000.00 in common stock, $-611388000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $87.08 million and cash and short-term investments were $334.29 million. The company’s total short-term debt was $802,000 while long-term debt stood at $4.71 million.

Viridian Therapeutics Inc’s total current assets stands at $346.33 million while long-term investments were $0 and short-term investments were $247.21 million. Its net receivables were $102000.00 compared to accounts payable of $4.13 million and inventory worth $0.

In 2024, Viridian Therapeutics Inc's operating cash flow was $40.71 million while its capital expenditure stood at $331000.

Comparatively, Viridian Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$17.75
52-Week High
$39
52-Week Low
$17.49
Analyst Target Price
$44

Viridian Therapeutics Inc stock is currently trading at $17.75 per share. It touched a 52-week high of $39 and a 52-week low of $39. Analysts tracking the stock have a 12-month average target price of $44.

Its 50-day moving average was $19.82 and 200-day moving average was $26.34 The short ratio stood at 12.33 indicating a short percent outstanding of 0%.

Around 148.5% of the company’s stock are held by insiders while 10065.9% are held by institutions.

Frequently Asked Questions About Viridian Therapeutics Inc

The stock symbol (also called stock or share ticker) of Viridian Therapeutics Inc is VRDN

The IPO of Viridian Therapeutics Inc took place on 2014-06-18

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$4.82
-0.05
-1.03%
$3.35
0.04
+1.21%
$12.3
0
0%
$2.53
0.04
+1.61%
$35.89
-1.88
-4.98%
$22.6
0.04
+0.18%
$4.21
0.05
+1.2%
$24.63
0.96
+4.06%
$224.3
-28.8
-11.38%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company’s product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-002 and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-004, a discovery-stage therapeutic antibody program for rare disease; and VRDN-005 and VRDN-006, a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. is headquartered in Waltham, Massachusetts.

Address

221 Crescent Street, Waltham, MA, United States, 02453